Programmable CRISPR tools are turning stem cell biology into something closer to software engineering, shrinking ...

Rare diseases pose unique challenges in the medical field, often affecting a small but vulnerable population with limited treatment options. The Rare Disease Challenge (RaDiChal) is a groundbreaking ...

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of ...

CRISPR's gene therapy, Casgevy, faces operational challenges and stiff competition from Lyfgenia, impacting its market adoption. The initial commercial rollout of gene therapies requires the ...

For years, Yale researchers David Breslow and Mustafa Khokha have worked together with a similar challenge in their ...

Crispr Therapeutics AG ( ($CRSP) ) has risen by 9.03%. Read on to learn why. Crispr Therapeutics AG has seen its stock price rise by 9.03% over ...

2023 was an important year for patients with sickle cell disease. Prior to CRISPR, the only cure for the life-long ailment was a bone marrow transplant, which is notoriously dangerous and costly. This ...

Despite a challenging CASGEVY launch, high cash burn, and an almost 10% YTD share count growth, CRISPR’s pipeline breadth and ...

Researchers used CRISPR to change the number of chromosomes in Arabidopsis by fusing chromosome arms, reducing the genome ...

A new genome editing technology known as CRISPR has the potential to revolutionize the way scientists study diseases and genetics. “I think it’s a really useful tool for science, in fact it’s sort of ...

Professor of Biomedical Engineering, Head of Biomedical Engineering Programme, Director of CUHKSZ-Boyalife Joint Laboratory of Regenerative Medicine Engineering, Team Leader of Integrated Devices and ...